Spinal Stabilization Technologies (SST) commenced the LOPAIN2 clinical trial of the PerQdisc™ Nucleus Replacement Device (NRD).
SST’s PerQdisc will be studied in patients with lumbar degenerative disc disease. SST’s PerQdisc NRD aims to treat discogenic low back pain while maintaining disc height and preserving range of motion.
This trial is enrolling 72 patients and taking place in research centers across South America. Data from the LOPAIN2 trials will be used to file for the CE Mark.
“We’re impressed with the quality of clinical trial research in the South American region,” said Mark Novotny, CEO of SST. “These are advanced research centers with fully staffed research teams. The patient care and follow-up are excellent. In an earlier trial, no patient was lost to follow-up. The surgeons and their research staff we are working with are all highly trained in clinical research and motivated to make our trials in South America a success.”
Spinal Stabilization Technologies (SST) commenced the LOPAIN2 clinical trial of the PerQdisc™ Nucleus Replacement Device (NRD).
SST's PerQdisc will be studied in patients with lumbar degenerative disc disease. SST's PerQdisc NRD aims to treat discogenic low back pain while maintaining disc height and preserving range of motion.
This trial...
Spinal Stabilization Technologies (SST) commenced the LOPAIN2 clinical trial of the PerQdisc™ Nucleus Replacement Device (NRD).
SST’s PerQdisc will be studied in patients with lumbar degenerative disc disease. SST’s PerQdisc NRD aims to treat discogenic low back pain while maintaining disc height and preserving range of motion.
This trial is enrolling 72 patients and taking place in research centers across South America. Data from the LOPAIN2 trials will be used to file for the CE Mark.
“We’re impressed with the quality of clinical trial research in the South American region,” said Mark Novotny, CEO of SST. “These are advanced research centers with fully staffed research teams. The patient care and follow-up are excellent. In an earlier trial, no patient was lost to follow-up. The surgeons and their research staff we are working with are all highly trained in clinical research and motivated to make our trials in South America a success.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
